[144] Mineralys Therapeutics, Inc. SEC Filing

Rhea-AI Filing Summary

Mineralys Therapeutics (MLYS) filed a Form 144 to notify a proposed sale of 11,365 shares of common stock, with an aggregate market value of $146,987.47. The shares were acquired on 08/12/2024 by cash exercise of employee stock options from Mineralys Therapeutics, Inc., and the proposed sale is to be executed through Merrill Lynch on NASDAQ with an approximate sale date of 08/13/2025. The company reports 66,295,184 shares outstanding.

The filing also discloses recent sales by the same seller: 11,366 shares sold on 06/13/2025 for $165,930.95 and 11,366 shares sold on 07/14/2025 for $165,878.90. The filer affirms they are not aware of undisclosed material information and includes the standard signature/representation language required by Rule 144.

Positive

• Acquisition method disclosed: shares were acquired by cash exercise of employee stock options on 08/12/2024
• Broker and market disclosed: planned sale to be executed through Merrill Lynch on NASDAQ, showing orderly brokerage execution

Negative

• Insider dispositions recorded: two prior sales of 11,366 shares each on 06/13/2025 and 07/14/2025 with gross proceeds of $165,930.95 and $165,878.90
• Additional proposed sale: seller filed to sell 11,365 shares (~$146,987.47), indicating continued insider selling activity

Insights

Securities Analyst

TL;DR: Routine Rule 144 disclosure of a small insider sale; transaction sizes are modest versus total shares outstanding.

The Form 144 reports a proposed sale of 11,365 shares valued at $146,987.47, acquired by cash exercise of employee stock options on 08/12/2024. With 66,295,184 shares outstanding, the proposed sale represents a de minimis portion of the float. Two recent prior sales of 11,366 shares each were reported in June and July 2025 with gross proceeds near $165.9k each. From a trading-impact perspective, these disclosures document compliance with Rule 144 but are unlikely to be material to valuation given the small percentage of outstanding shares.

Corporate Governance Expert

TL;DR: The filing is a standard insider sale notice that documents option exercise and ongoing dispositions; includes required attestation language.

The notice identifies the securities as acquired via cash purchase of employee stock options and names Merrill Lynch as the broker for the planned sale on NASDAQ. The filing reiterates the seller's representation of no undisclosed material information and provides a record of recent sales in June and July 2025. For governance review, the form supplies expected transparency on insider activity; the disclosed quantities are small relative to total shares outstanding and do not, by themselves, indicate governance or disclosure deficiencies.

08/13/2025 - 05:21 PM

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Merrill Lynch 225 Liberty St Floor 37 New York NY 10281	11365	146987.47	66295184	08/13/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	08/12/2024	Cash purchase of employee stock options	Mineralys Therapeutics, Inc.			11365	08/12/2024	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
David Rodman 150 N. RADNOR CHESTER ROAD SUITE F200 RADNOR PA 19087	Common Stock	06/13/2025	11366	165930.95
David Rodman 150 N. RADNOR CHESTER ROAD SUITE F200 RADNOR PA 19087	Common Stock	07/14/2025	11366	165878.90

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the MLYS Form 144 disclose?

The Form 144 discloses a proposed sale of 11,365 shares valued at $146,987.47, acquired by cash exercise of employee stock options on 08/12/2024.

When and where is the proposed sale to occur for MLYS?

The filing lists an approximate sale date of 08/13/2025 with execution through Merrill Lynch on NASDAQ.

How many shares of MLYS are outstanding according to the filing?

The filing reports 66,295,184 shares outstanding.

Were there recent insider sales reported for MLYS?

Yes. The filing reports two sales by the seller: 11,366 shares on 06/13/2025 (gross proceeds $165,930.95) and 11,366 shares on 07/14/2025 (gross proceeds $165,878.90).

How were the securities originally acquired?

The securities to be sold were acquired on 08/12/2024 by cash purchase of employee stock options from Mineralys Therapeutics, Inc.